Market Closed -
Hong Kong S.E.
09:08:03 23/05/2024 BST
|
5-day change
|
1st Jan Change
|
1.4
HKD
|
-4.11%
|
|
+0.72%
|
+17.65%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
8,266
|
2,895
|
1,172
|
544.8
|
Enterprise Value (EV)
1 |
5,367
|
752.1
|
-387.7
|
-613.5
|
P/E ratio
|
-1.36
x
|
-3.28
x
|
-1.62
x
|
-0.81
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
800
x
|
-
|
73.6
x
|
-
|
EV / Revenue
|
519
x
|
-
|
-24.3
x
|
-
|
EV / EBITDA
|
-5.82
x
|
-0.9
x
|
0.52
x
|
1.11
x
|
EV / FCF
|
-9,196,255
x
|
-1,868,331
x
|
1,044,027
x
|
2,782,175
x
|
FCF Yield
|
-0%
|
-0%
|
0%
|
0%
|
Price to Book
|
2.55
x
|
1.15
x
|
0.65
x
|
0.46
x
|
Nbr of stocks (in thousands)
|
491,030
|
500,474
|
499,058
|
503,733
|
Reference price
2 |
16.83
|
5.785
|
2.349
|
1.082
|
Announcement Date
|
27/04/21
|
28/04/22
|
28/04/23
|
25/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
6.882
|
13.04
|
10.33
|
-
|
15.93
|
-
|
EBITDA
1 |
-265.2
|
-493.7
|
-921.9
|
-840.2
|
-748.6
|
-551
|
EBIT
1 |
-293.2
|
-524.6
|
-958.4
|
-884.2
|
-785.2
|
-616.3
|
Operating Margin
|
-4,260.93%
|
-4,023.03%
|
-9,276.55%
|
-
|
-4,928.55%
|
-
|
Earnings before Tax (EBT)
1 |
-288.1
|
-523.6
|
-3,036
|
-866.3
|
-732.4
|
-677.5
|
Net income
1 |
-288.1
|
-522.1
|
-3,027
|
-865.2
|
-730.2
|
-674.4
|
Net margin
|
-4,185.95%
|
-4,004%
|
-29,301.15%
|
-
|
-4,583.32%
|
-
|
EPS
2 |
-1.122
|
-1.888
|
-12.36
|
-1.766
|
-1.448
|
-1.332
|
Free Cash Flow
|
-
|
511.2
|
-583.6
|
-402.5
|
-371.4
|
-220.5
|
FCF margin
|
-
|
3,920.79%
|
-5,648.94%
|
-
|
-2,330.85%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/06/20
|
30/06/20
|
27/04/21
|
28/04/22
|
28/04/23
|
25/04/24
|
Fiscal Period: December |
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
---|
Net sales
1 |
3.76
|
6.57
|
-
|
-
|
2.956
|
12.98
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
-416.1
|
-502.6
|
-440.1
|
-346.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-14,887.79%
|
-2,667.4%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-405.6
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-13,722.29%
|
-
|
EPS
2 |
-
|
-
|
-0.8200
|
-0.9300
|
-0.8100
|
-0.6400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/09/21
|
23/03/21
|
26/08/21
|
30/03/22
|
30/08/22
|
30/03/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
80.4
|
212
|
2,899
|
2,143
|
1,560
|
1,158
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
511
|
-584
|
-403
|
-371
|
-221
|
ROE (net income / shareholders' equity)
|
-
|
-99.7%
|
-175%
|
-30.2%
|
-34%
|
-45.1%
|
ROA (Net income/ Total Assets)
|
-
|
-38.1%
|
-27.8%
|
-17.2%
|
-19.7%
|
-21.6%
|
Assets
1 |
-
|
1,370
|
10,882
|
5,039
|
3,703
|
3,118
|
Book Value Per Share
2 |
3.210
|
0.7900
|
6.610
|
5.020
|
3.590
|
2.360
|
Cash Flow per Share
2 |
0.4900
|
0.9200
|
5.990
|
4.440
|
3.170
|
2.310
|
Capex
1 |
27.6
|
20.6
|
28.3
|
46.5
|
9.04
|
1.03
|
Capex / Sales
|
401.58%
|
157.93%
|
274.1%
|
-
|
56.74%
|
-
|
Announcement Date
|
30/06/20
|
30/06/20
|
27/04/21
|
28/04/22
|
28/04/23
|
25/04/24
|
|
1st Jan change
|
Capi.
|
---|
| +17.65% | 95.17M | | +10.61% | 115B | | +12.18% | 106B | | -5.68% | 24.69B | | -2.33% | 21.97B | | -6.03% | 19.27B | | -13.72% | 17.56B | | -40.50% | 17.32B | | +6.61% | 14.03B | | +30.50% | 12.13B |
Bio Therapeutic Drugs
|